• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Drug­mak­ers stock­pile in­ven­to­ry in the US, seek­ing to get ahead of Trump tar­iffs

Last month
China
Pharma

Pre­ven­tive health start­up Su­per­pow­er rais­es $30M

Last month
Financing
Health Tech

As the XBI suf­fers, Q1 shows a few com­fort­ing signs of un­der­ly­ing sta­bil­i­ty

Last month
Bioregnum

Up­dat­ed: Roche’s $50B US in­vest­ment in­cludes pre­vi­ous build an­nounce­ments

Last month
Pharma
Manufacturing

As­traZeneca, Dai­ichi eye first-line breast can­cer mar­ket af­ter En­her­tu's ear­ly Phase 3 win

Last month
R&D
Pharma

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

Last month
FDA+

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Last month
FDA+

Alvo­gen unit ap­peals court loss shield­ing Bausch Health's IBS drug from gener­ics

Last month
Pharma
FDA+

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Last month
Startups
R&D

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Last month
R&D

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

Last month
People
R&D

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Last month
FDA+

Trump’s ex­ec­u­tive or­der on drug pric­ing; Pfiz­er drops oral obe­si­ty drug; Seed rounds at their low­est in years; and ...

Last month
Weekly

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

Last month
Startups
Deals

GSK kicks off Blenrep re­launch plans with clear­ance from UK reg­u­la­tors

Last month
Pharma
FDA+

CMS would ab­sorb 340B drug dis­count pro­gram un­der leaked HHS re­or­ga­ni­za­tion pro­pos­al

Last month
Pharma
FDA+

Roche dis­con­tin­ues low dose in Hunt­ing­ton’s tri­al, will switch pa­tients to high dose

Last month
R&D

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Last month
Pharma
Manufacturing

What it took for Wal­greens to go pri­vate

Last month
Health Tech

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Last month
Deals

Bay­er opens $44M US ex­pan­sion; Meri­bel CD­MO launch­es in Eu­rope

Last month
Manufacturing

Unit­ed­Health re­ports 'unusu­al and un­ac­cept­able' earn­ings as Medicare costs climb

Last month
Health Tech

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

Last month
Financing
R&D

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Last month
Peer Review
First page Previous page 12131415161718 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times